180 related articles for article (PubMed ID: 20353421)
1. Proteomic analysis of osteogenic sarcoma: association of tumour necrosis factor with poor prognosis.
Cates JM; Friedman DB; Seeley EH; Dupont WD; Schwartz HS; Holt GE; Caprioli RM; Young PP
Int J Exp Pathol; 2010 Aug; 91(4):335-49. PubMed ID: 20353421
[TBL] [Abstract][Full Text] [Related]
2. Expression of macrophage migration inhibitory factor relates to survival in high-grade osteosarcoma.
Han I; Lee MR; Nam KW; Oh JH; Moon KC; Kim HS
Clin Orthop Relat Res; 2008 Sep; 466(9):2107-13. PubMed ID: 18563508
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a pretreatment prognostic index to predict death and lung metastases in extremity osteosarcoma.
Wang B; Tu J; Yin J; Zou C; Wang J; Huang G; Xie X; Shen J
Oncotarget; 2015 Nov; 6(35):38348-59. PubMed ID: 26435480
[TBL] [Abstract][Full Text] [Related]
4. Elevated Expression of Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) Is Associated With a Poor Prognosis in Osteosarcoma.
Matsuda K; Miyoshi H; Hiraoka K; Hamada T; Nakashima K; Shiba N; Ohshima K
Clin Orthop Relat Res; 2018 Sep; 476(9):1848-1855. PubMed ID: 30024460
[TBL] [Abstract][Full Text] [Related]
5. Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma.
Dumars C; Ngyuen JM; Gaultier A; Lanel R; Corradini N; Gouin F; Heymann D; Heymann MF
Oncotarget; 2016 Nov; 7(48):78343-78354. PubMed ID: 27823976
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study.
Urakawa H; Nishida Y; Naruse T; Nakashima H; Ishiguro N
Clin Orthop Relat Res; 2009 Nov; 467(11):2932-8. PubMed ID: 19326179
[TBL] [Abstract][Full Text] [Related]
7. XB130 expression in human osteosarcoma: a clinical and experimental study.
Wang X; Wang R; Liu Z; Hao F; Huang H; Guo W
Int J Clin Exp Pathol; 2015; 8(3):2565-73. PubMed ID: 26045762
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
[TBL] [Abstract][Full Text] [Related]
9. pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.
Thanapprapasr K; Nartthanarung A; Thanapprapasr D; Jinawath A
PLoS One; 2017; 12(8):e0182989. PubMed ID: 28846700
[TBL] [Abstract][Full Text] [Related]
10. p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities: an analysis of 357 cases.
Righi A; Gambarotti M; Sbaraglia M; Sisto A; Ferrari S; Dei Tos AP; Picci P
Hum Pathol; 2016 Dec; 58():15-23. PubMed ID: 27544803
[TBL] [Abstract][Full Text] [Related]
11. Descriptive epidemiology and outcomes of bone sarcomas in adolescent and young adult patients in Japan.
Fukushima T; Ogura K; Akiyama T; Takeshita K; Kawai A
BMC Musculoskelet Disord; 2018 Aug; 19(1):297. PubMed ID: 30121085
[TBL] [Abstract][Full Text] [Related]
12. High expression of tumor endothelial marker 7 is associated with metastasis and poor survival of patients with osteogenic sarcoma.
Fuchs B; Mahlum E; Halder C; Maran A; Yaszemski M; Bode B; Bolander M; Sarkar G
Gene; 2007 Sep; 399(2):137-43. PubMed ID: 17560052
[TBL] [Abstract][Full Text] [Related]
13. Expression and prognostic relevance of centromere protein A in primary osteosarcoma.
Gu XM; Fu J; Feng XJ; Huang X; Wang SM; Chen XF; Zhu MH; Zhang SH
Pathol Res Pract; 2014 Apr; 210(4):228-33. PubMed ID: 24440098
[TBL] [Abstract][Full Text] [Related]
14. Vitronectin significantly influences prognosis in osteosarcoma.
Shi K; Lan RL; Tao X; Wu CY; Hong HF; Lin JH
Int J Clin Exp Pathol; 2015; 8(9):11364-71. PubMed ID: 26617861
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of macrophage migration inhibitory factor expression in patients with squamous cell carcinoma of the lung.
Koh HM; Kim DC; Kim YM; Song DH
Thorac Cancer; 2019 Dec; 10(12):2209-2217. PubMed ID: 31602798
[TBL] [Abstract][Full Text] [Related]
16. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials.
Livingston JA; Hess KR; Naing A; Hong DS; Patel S; Benjamin RS; Ludwig JA; Conley A; Herzog CE; Anderson P; Meric-Bernstam F; Kurzrock R; Subbiah V
Oncotarget; 2016 Sep; 7(39):64421-64430. PubMed ID: 27486883
[TBL] [Abstract][Full Text] [Related]
17. Analysis of HSP27 and the Autophagy Marker LC3B
Livingston JA; Wang WL; Tsai JW; Lazar AJ; Leung CH; Lin H; Advani S; Daw N; Santiago-O'Farrill J; Hollomon M; Gordon NB; Kleinerman ES
Mol Cancer Ther; 2018 Jun; 17(6):1315-1323. PubMed ID: 29592877
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of non-osteogenic, non-Ewing soft-tissue sarcoma of bone--experience of the Toronto Sarcoma Program.
Veitch ZW; Fasih S; Griffin AM; Al-Ezzi EM; Gupta AA; Ferguson PC; Wunder JS; Abdul Razak AR
Cancer Med; 2020 Dec; 9(24):9282-9292. PubMed ID: 33063945
[TBL] [Abstract][Full Text] [Related]
19. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma.
Abdeen A; Chou AJ; Healey JH; Khanna C; Osborne TS; Hewitt SM; Kim M; Wang D; Moody K; Gorlick R
Cancer; 2009 Nov; 115(22):5243-50. PubMed ID: 19670450
[TBL] [Abstract][Full Text] [Related]
20. High WT1 expression is associated with very poor survival of patients with osteogenic sarcoma metastasis.
Srivastava A; Fuchs B; Zhang K; Ruan M; Halder C; Mahlum E; Weber K; Bolander ME; Sarkar G
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4237-43. PubMed ID: 16857797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
